Image Guided Therapy in the Treatment of Gliomas

Stopped early · Not applicable

Conditions studied: Glioma

In brief

RATIONALE: New imaging techniques using magnetic resonance imaging give better tumor definition, thus may lead to better tumor targeting and avoid damaging critical parts of normal brain. PURPOSE: This phase I/II trial is studying how well image-guided therapy works in treating patients with newly diagnosed intracranial glioma.

Key facts

Study ID

NCT01263821

Run by

NYU Langone Health

People needed

15

Starts

2009-08-01

Expected to finish

2014-04-01

Last updated by the study team

2017-08-04

Who can join

Age: 7 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed, newly diagnosed intracranial glioma
• A diagnostic contrast enhanced CT/MRI demonstrating the lesion prior to registration
• Karnofsky performance status >= 60
• Ability to undergo MR imaging with the use of Gadolinium dye
• Patient must sign a study specific informed consent form; if the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the patient's legal representative

You may not qualify if…

• Inability to obtain histological proof of glioma
• Allergy to Gadolinium contrast
• Any condition including metallic implants or cardiac pace makers that make the candidate ineligible for MR imaging
• Any medical condition including renal or cardiac insufficiency that make the candidate a high risk for gadolinium contrast administration
• Karnofsky performance status of =< 50
• Prior history of radiation therapy to the brain
• Pregnancy

Where it is running

• NYU Cancer Institute — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.